Clinical trial Recruiting at 1 site Interventional Ages 20 to 60

Comparing rivaroxaban and enoxaparin for preventing blood clots in obese patients undergoing weight loss surgery

Official title: Rivaroxaban Versus Enoxaparin for Prophylaxis of Venous Thromboembolism in Morbidly Obese Patients Undergoing Bariatric Surgery: An open_label Randomized Controlled Trial

Run by Alexandria University · NCT06689241 · Data updated 2026-11-12

This study tests whether the blood thinner rivaroxaban works better than enoxaparin to prevent blood clots in obese patients having weight loss surgery.

More Bariatric Surgery Candidate trials

Quick facts

Study typeInterventional
Ages20 Years to 60 Years
SexAll
Enrollment162 (estimated)
SponsorAlexandria University
Academic / other
Locations1 site (Alexandria)
StatusRecruiting
StartedOctober 1, 2024
Main results expectedDecember 1, 2025
Study endsMay 1, 2026
Registry record updatedApril 22, 2025
Trial IDNCT06689241 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals aged 20-60 years with a BMI between 35-50 kg/m² who are classified as ASA physical status class I to III.

Probably not a fit

Patients with severe cardiac disorders, chronic renal failure, liver cirrhosis, or major psychological disorders may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the effectiveness of rivaroxaban compared to enoxaparin for the prevention of venous thromboembolism (VTE) in morbidly obese patients who are candidates for bariatric surgery. The study is an open-label randomized controlled trial that aims to determine which medication is more effective in reducing the risk of post-operative blood clots. Given the rising prevalence of obesity and the associated risks of VTE, this research addresses a critical public health issue. Participants will be monitored for VTE incidence following their surgical procedures to assess the outcomes of each treatment.

Why it matters

Potential benefit: If successful, this study could lead to improved prophylactic strategies for preventing life-threatening blood clots in obese patients undergoing bariatric surgery.

How similar studies have gone: Other studies have explored the use of anticoagulants for VTE prevention in surgical patients, but this specific comparison of rivaroxaban and enoxaparin in the context of bariatric surgery is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age: 20-60 years, both sexes.
* ASA physical status class I to III.
* BMI 35-50 kg/m²

Exclusion Criteria:

* Severe cardiac disorder
* chronic renal failure
* liver cirrhosis
* major psychological disorder

Where it's running

  • Alexandria University
    Alexandria, Egypt
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.